Epidemiology of Escherichia coli bloodstream infection antimicrobial resistance trends across South West England during the first 2 years of the coronavirus disease 2019 pandemic response

被引:2
|
作者
Stanley, Jack [1 ]
Sullivan, Brian [1 ]
Dowsey, Andrew W. [1 ]
Jones, Koren [2 ,3 ]
Beck, Charles R. [2 ,3 ,4 ]
机构
[1] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, England
[2] UK Hlth Secur Agcy, Evaluat & Epidemiol Sci Div, Sci Grp, Porton Down, England
[3] UK Hlth Secur Agcy, Field Serv South West, Hlth Protect Operat, Bristol, England
[4] Univ Bristol, Natl Inst Hlth, Res Hlth Protect Res Unit Behav Sci & Evaluat, Bristol, England
关键词
Antimicrobial resistance; COVID-19; Epidemiology; Escherichia coli; Gram negative; Non-pharmaceutical intervention;
D O I
10.1016/j.cmi.2024.03.018
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Between 2016 and 2019, the proportion of Escherichia coli bloodstream infection (BSI) with resistance to at least one antibiotic increased nationally. Public health interventions implemented in response to the COVID-19 pandemic changed population contact patterns and healthcare systems, with consequent effects on epidemiological trends of numerous pathogens. We investigated the impact of COVID-19 restrictions on epidemiological trends of E. coli BSI antimicrobial resistance (AMR) across South West England. Methods: We undertook a retrospective ecological analysis utilizing routine surveillance data of E. coli BSI cases reported to the UK Health Security Agency between 2016 and 2021. We analysed AMR trends for antimicrobial agents including amoxicillin-clavulanate, ciprofloxacin, piperacillin-tazobactam, gentamicin, third-generation cephalosporins and carbapenems before and after the implementation of COVID-19 restrictions (23 March 2020) using Bayesian segmented regression. Results: We identified 19 055 cases. A total of 50.2% were male. Median age was 76 (interquartile range, 65-85 years). Piperacillin-tazobactam (-2.90% [95% highest density interval {HDI}-4.51%,-0.48%]) and ciprofloxacin (-2.40% [95% HDI-4.35%, 0.48%]) resistance demonstrated immediate step changes at the implementation of COVID-19 restrictions. Gentamicin (odds ratio [OR] 0.92 [95% HDI 0.76, 1.12]) and third-generation cephalosporins (OR 0.95 [95% HDI 0.80, 1.14]) exhibited decreasing annual resistance trends after the implementation of COVID-19 restrictions, with moderate evidence for a lower OR after restrictions as compared to the period before (gentamicin Bayes Factor = 5.10, third-generation cephalosporins Bayes Factor = 6.67). Discussion: COVID-19 restrictions led to abrupt and longer term changes to E.coli BSI AMR. The immediate effects suggest altered transmission, whereas changes to resistant E. coli reservoirs may explain trend effects. Jack Stanley, Clin Microbiol Infect 2024;30:1291 Crown Copyright (c) 2024 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).
引用
收藏
页码:1291 / 1297
页数:7
相关论文
共 2 条
  • [1] Antimicrobial Resistance and Molecular Epidemiology of Escherichia coli From Bloodstream Infection in Shanghai, China, 2016-2019
    Xiao, Shuzhen
    Tang, Chenyue
    Zeng, Qian
    Xue, Yilun
    Chen, Qing
    Chen, Erzhen
    Han, Lizhong
    FRONTIERS IN MEDICINE, 2022, 8
  • [2] Trends in non-fatal and fatal opioid overdoses during the first two years of the coronavirus disease-2019 pandemic
    Abasilim, Chibuzor
    Friedman, Lee S.
    Karch, Lydia
    Holloway-Beth, Alfreda
    ANNALS OF EPIDEMIOLOGY, 2024, 90 : 35 - 41